Sugi Predict

Sugi Predict / Compounds / SCHEMBL2278207

SCHEMBL2278207

SCHEMBL2278207

COC(=O)C1CN1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.48
▸ NR1H3 Q13133 1/20 0.48
▸ PTPN1 P18031 1/20 0.45
▸ MMP2 P08253 1/20 0.41
▸ ANPEP P15144 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PDE4B Q07343 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ FKBP1A P62942 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3786077 1.00 NR1H2 (0.48) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL2798703 1.00 NR1H2 (0.48) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL30401835 0.98 NR1H2 (0.47) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL2253790 0.85 MMP2 (0.43) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL18589421 0.85 PEPD (0.47) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL24645309 0.85 PEPD (0.47) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL6122335 0.85 MMP2 (0.43) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL6848252 0.85 MMP2 (0.43) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL3789795 0.85 CYP3A4 (0.53) NR1H2NR1H3PTPN1MMP2ANPEP
SCHEMBL882756 0.85 PEPD (0.47) NR1H2NR1H3PTPN1MMP2ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133234-A1 SORTILIN BINDERS AND BIFUNCTIONAL COMPOUNDS THEREOF DRAUPNIR BIO APS (DK) 2025-06-26 — — WO disclosed
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-06-12 — — US disclosed
EP-4551555-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
CN-119677716-A Pharmaceutical compositions comprising WRN helicase inhibitors 维维迪恩医疗公司 2025-03-21 — — CN disclosed
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors VIVIDION THERAPEUTICS, INC. 2025-01-07 — — US disclosed
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 — — US disclosed
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-05-02 — — US disclosed
CN-117603075-B Preparation method of carbon 13-marked 3-carboxylic phenylalanine 深圳创元生物医药科技有限公司 2024-04-12 — — CN disclosed
US-20240067612-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-02-29 — — US disclosed
CN-117603075-A Preparation method of carbon 13-marked 3-carboxylic phenylalanine 深圳创元生物医药科技有限公司 2024-02-27 — — CN disclosed
WO-2010091104-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS EXELIXIS, INC. (US) 2010-08-12 — — WO disclosed
WO-2010091164-A1 INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE EXELIXIS, INC. (US) 2010-08-12 — — WO disclosed
US-7498356-B2 Substituted amino carboxylic acids THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) 2009-03-03 — — US disclosed
US-7498356-B2 Substituted amino carboxylic acids THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) 2009-03-03 — — US disclosed
EP-1685102-A4 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD (KR) 2008-08-20 — — EP disclosed
US-20070129346-A1 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2007-06-07 — — US disclosed
EP-1685102-A1 MELANOCORTIN RECEPTOR AGONISTS LG Life Sciences Ltd. (KR) 2006-08-02 — — EP disclosed
WO-2005047253-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 — — WO disclosed
WO-2005047251-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 — — WO disclosed
CN-1440400-A Bicyelyl or heterobicyclylmethanesulfonylamino-substituted N-hydroxyformamides SMITHKLINE BEECHAMP P L C (GB) 2003-09-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF ITGB1, ITGA1, ITGAV NR1H2 2279/4885NR1H3 2251/4885PTPN1 1542/4885
US-20240067612-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN NR1H2 1276/4885NR1H3 1495/4885PTPN1 2795/4885
US-20070129346-A1 Melanocortin receptor agonists MC1R, MC3R, MC5R NR1H2 556/4885NR1H3 626/4885PTPN1 1093/4885
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN NR1H2 1276/4885NR1H3 1495/4885PTPN1 2795/4885
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors RECQL, BLM, WRN NR1H2 1276/4885NR1H3 1495/4885PTPN1 2795/4885
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN NR1H2 1276/4885NR1H3 1495/4885PTPN1 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.